Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease CRANBURY, N.J., May 27, 2025--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing an integrated pipeline of genetic therapies for rare diseases,...

#RocketPharmaceutical reports patient death in systemic AAV9-based #Danon gene therapy program. Suspects immune suppression to be culprit.

Except for post-Rx steroids, experimentation w/ novel immune suppression regimens doing more harm than good it seems. #AAV

finance.yahoo.com/news/rocket-...